Back to top
more

Zimmer Biomet (ZBH)

(Delayed Data from NYSE)

$108.18 USD

108.18
1,175,736

-0.51 (-0.47%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $108.25 +0.07 (0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (74 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zimmer Biomet (ZBH) to Broaden Knee Surgery Line With New Alliance

by Zacks Equity Research

Zimmer Biomet (ZBH) joins forces with Think Surgical for the distribution of customized TMINI - Miniature Robotic System in the U.S. market.

Zimmer Biomet (ZBH) Procedure Recovery Aids Amid Macro Woes

by Zacks Equity Research

Zimmer Biomet (ZBH) continues to record strong procedure volume in 2024 in both the Knees and Hips businesses, banking on an improved market scenario.

Zimmer Biomet (ZBH) Unlocks Growth Plan for Future Success

by Zacks Equity Research

Zimmer Biomet (ZBH) outlines a path for compelling and long-term topline growth, improved operational profitability, and increased free cash flow generation.

Zimmer Biomet (ZBH) is a Top-Ranked Value Stock: Should You Buy?

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Here's Why You Should Retain Zimmer Biomet (ZBH) Stock for Now

by Zacks Equity Research

Strong procedure recovery and progress on the four-pillar strategy bode well for Zimmer Biomet (ZBH).

Here's Why Zimmer Biomet (ZBH) is a Strong Value Stock

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

The Zacks Analyst Blog Highlights Amazon, Visa, Pfizer, Martin Marietta Materials and Zimmer Biomet

by Zacks Equity Research

Amazon, Visa, Pfizer, Martin Marietta Materials and Zimmer Biomet are included in this Analyst Blog.

Mark Vickery headshot

Top Stock Reports for Amazon.com, Visa & Pfizer

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), Visa Inc. (V) and Pfizer Inc. (PFE).

Zimmer Biomet (ZBH) Q1 Earnings Beat, Margins Expand

by Zacks Equity Research

Each of Zimmer Biomet's (ZBH) geographic segments records strong year-over-year sales growth on a reported basis, as well as at CER.

Zimmer (ZBH) Reports Q1 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

While the top- and bottom-line numbers for Zimmer (ZBH) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zimmer Biomet (ZBH) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Zimmer (ZBH) delivered earnings and revenue surprises of 3.74% and 1.16%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Urmimala Biswas headshot

Will These 5 MedTech Stocks Beat Forecasts This Earnings Season?

by Urmimala Biswas

Here is a sneak peek into how the five MedTech stocks, HOLX, ZBH, ILMN, TFX and BRKR, are expected to fare in their quarterly results slated to be released tomorrow.

Earnings Preview: biote Corp. (BTMD) Q1 Earnings Expected to Decline

by Zacks Equity Research

Biote Corp. (BTMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Unlocking Q1 Potential of Zimmer (ZBH): Exploring Wall Street Estimates for Key Metrics

by Zacks Equity Research

Besides Wall Street's top -and-bottom-line estimates for Zimmer (ZBH), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.

Baxter (BAX) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Baxter's (BAX) first-quarter results are likely to reflect growth in elective surgical procedures and a more stable supply chain.

Why Zimmer (ZBH) is Poised to Beat Earnings Estimates Again

by Zacks Equity Research

Zimmer (ZBH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Here's Why Zimmer Biomet (ZBH) is a Strong Value Stock

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Earnings Preview: Zimmer Biomet (ZBH) Q1 Earnings Expected to Decline

by Zacks Equity Research

Zimmer (ZBH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Urmimala Biswas headshot

SYK vs ZBH: Which Stock Looks More Promising Ahead of Q1 Earnings?

by Urmimala Biswas

SYK and ZBH are expected to have witnessed strong procedural volume growth across the global market in the first quarter.

What's in the Cards for Zimmer Biomet (ZBH) in Q1 Earnings?

by Zacks Equity Research

Within the Hips business, Zimmer Biomet (ZBH) is expected to have witnessed procedure volume recovery, banking on strategic product launches in the first quarter.

Smith+Nephew (SNN) Expands in Australia With New Alliance

by Zacks Equity Research

The latest partnership allows Smith+Nephew (SNN) to complement its existing implant range with the cutting-edge navigation technology of NAVBIT.

Why Zimmer Biomet (ZBH) is a Top Value Stock for the Long-Term

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Tenet (THC) Divests Six Hospitals, Sustains Divestiture Spree

by Zacks Equity Research

Tenet Healthcare (THC) completes the sale of six California hospitals, four to UCI Health and two to Adventist Health, to refine the portfolio and reduce debt burden.

Indrajit Bandyopadhyay headshot

5 Medical Product Stocks to Buy Amid Industry Challenges

by Indrajit Bandyopadhyay

Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. SYK, RMD, ZBH, PODD and LNTH are well-poised to gain from the favorable factors.

Here's Why You Should Buy Zimmer Biomet (ZBH) Stock Now

by Zacks Equity Research

Investors are optimistic about Zimmer Biomet (ZBH), led by expansion in the knee business and recovery across the business.